Form 4: Palatin Technologies Director John K.A. Prendergast Receives Stock Options and Restricted Share Units

Director John K.A. Prendergast of Palatin Technologies received stock options and restricted share units on July 15, 2024, following certification related to the company's 2011 Stock Incentive Plan.

Summary

• On July 15, 2024, John K.A. Prendergast, a director at Palatin Technologies, acquired 16,000 shares of common stock through restricted share units and options to purchase 23,000 shares.
• The restricted share units were granted under the 2011 Stock Incentive Plan and vest on June 4, 2025.
• The stock options have an exercise price of $1.83 and also vest on June 4, 2025, with vesting prorated monthly if the director doesn't serve until June 30, 2025.
• These grants were initially approved by the Compensation Committee on June 4, 2024, but were contingent on the Chief Financial Officer's certification that shareholders had increased the shares reserved under the 2011 Stock Incentive Plan and that there were no impediments to the grant of the options, which was completed on July 15, 2024.
• Following these transactions, Prendergast directly owns 63,310 shares of common stock and holds options for 83,280 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of restricted share units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service by the director.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of equity grant is a common practice for aligning the interests of company directors with those of shareholders in the biotechnology industry.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options and restricted stock units to incentivize their board members.
• The vesting schedules and exercise prices are generally aligned with industry norms to encourage long-term value creation.

Stakeholder Impact

• The grant of equity to the director could have a slightly positive impact on shareholders by aligning interests.
• There is no immediate impact on employees, customers, suppliers, or creditors.

Key Dates